Linked Life Data

1628691

Source:http://linkedlifedata.com/resource/pubmed/id/1628691

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1992-8-18
pubmed:abstractText
Serum concentration profiles and pharmacokinetic parameters (cmax, tmax, AUC24, AUC0-00, MRT) of ethinylestradiol (EE2) and levonorgestrel (LNG) were obtained following administration of two combined oral contraceptives. The constituents of the preparations were as follows: Gravistat (0.05 mg EE2, 0.125 mg LNG); Minisiston (0.03 mg EE2, 0.125 mg LNG). In 20 of the volunteers blood samples were taken before and up to 36 hours following the intake of a single table. In 11 women the investigation was carried out at day 21 of a treatment cycle (steady-state condition). In spite of pronounced interindividual variations of the pharmacokinetic data, a clear dependency of EE2 concentration curves on the estrogen dose of the respective preparation could be demonstrated. Under the condition of steady-state (21st day of administration) there was a slight but significant rise of the EE2 peak serum concentrations and a pronounced increase of the LNG levels, closely reflected by elevation of the AUC values. SHBG serum concentration was significantly increased by the 10th day of treatment in all subjects receiving Gravistat, whereas the mean value in the Minisiston-group did not remarkably change. Although LNG is known to be bound to SHBG with high affinity, the missing parallelism between LNG- and SHBG-concentrations suggests other (additional?) mechanisms for the elevated LNG-binding capacity in women taking combined EE2-LNG preparations.
pubmed:keyword
http://linkedlifedata.com/resource/pubmed/keyword/Contraception, http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive Agents--analysis, http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive..., http://linkedlifedata.com/resource/pubmed/keyword/Contraceptive..., http://linkedlifedata.com/resource/pubmed/keyword/Ethinyl Estradiol--analysis, http://linkedlifedata.com/resource/pubmed/keyword/Ethinyl Estradiol--pharmacodynamics, http://linkedlifedata.com/resource/pubmed/keyword/Examinations And Diagnoses, http://linkedlifedata.com/resource/pubmed/keyword/Family Planning, http://linkedlifedata.com/resource/pubmed/keyword/Laboratory Examinations And Diagnoses, http://linkedlifedata.com/resource/pubmed/keyword/Levonorgestrel--analysis, http://linkedlifedata.com/resource/pubmed/keyword/Levonorgestrel--pharmacodynamics, http://linkedlifedata.com/resource/pubmed/keyword/Oral...
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0232-7384
pubmed:author
pubmed:issnType
Print
pubmed:volume
99
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
12-7
pubmed:dateRevised
2004-11-17
pubmed:otherAbstract
PIP: Serum concentration profiles and pharmacokinetic parameters of ethinyl estradiol (EE2) and levonorgestrel (LNG) were obtained after administration of 2 combined oral contraceptives (OCs). The constituents of the preparations were as follows: Gravistat (0.05 mg EE2, 0.125 mg LNG); Minisiston (0.03 mg EE2, 0.125 mg LNG). Blood samples were taken before and up to 36 hours after intake of a single tablet by 20 volunteers. In 11 women, the investigation was conducted on day 21 of a treatment cycle (steady-state condition). In spite of pronounced interindividual variations of the pharmacokinetic data, a clear dependency of EE2 concentration curves on estrogen dose of the respective preparation could be demonstrated. With the condition of steady-state (21st day of administration), there was a slight but significant rise of EE2 peak serum concentrations and a pronounced increase in LNG levels, closely reflected by the elevation of the area under curve values. Sex hormone binding globulin (SHBG) serum concentration was significantly increased by day 10 of treatment in all those receiving Gravistat, whereas the mean value in the Minisiston group did not change remarkably. Although LNG is known to be bound to SHBG with high affinity, the missing parallelism between LNG and SHBG concentrations suggests other, possibly additional, mechanisms for the elevated LNG-binding capacity in those women taking combined EE2-LNG preparations.
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
pubmed:affiliation
Department of Obstetrics and Gynecology, Friedrich Schiller University, Medical School, Jena, Germany.
pubmed:publicationType
Journal Article